Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

JUN 27 2022

Liquidia Corporation Added to Russell 2000® and 3000® Indexes

MORRISVILLE, N.C. , June 27, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on June 27 , as part of the 2022 Russell indexes reconstitution.
JUN 24 2022

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C. , June 24, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of inducement stock options exercisable for an aggregate of 24,800 shares of Liquidia’s common stock to newly hired non-executive employees under the Liquidia Corporation 2022

btn News